ENXTPA:MEDCL
ENXTPA:MEDCLPharmaceuticals

MedinCell (ENXTPA:MEDCL): Assessing Valuation After Teva’s FDA Filing for Olanzapine Long-Acting Injectable

MedinCell (ENXTPA:MEDCL) has been in focus after partner Teva filed a New Drug Application with the U.S. FDA for its olanzapine long acting injectable, which is built on MedinCell’s BEPO technology. See our latest analysis for MedinCell. The latest regulatory milestone appears to have reignited interest in MedinCell, with the 1 day share price return of 3.85 percent and a 90 day share price return of 41.39 percent contributing to a robust 1 year total shareholder return of 77.19 percent. This...
ENXTPA:ERF
ENXTPA:ERFLife Sciences

Is Eurofins Scientific Fairly Priced After Portfolio Streamlining and 2025 Share Price Rebound?

If you have been wondering whether Eurofins Scientific is still a quality stock at a fair price, you are not alone, as many investors are trying to figure out if the current share price matches its long term potential. Despite a choppy few weeks, with the share price down 4.4% over the last 7 days and 2.6% over the last month, Eurofins is still up 16.3% year to date and 20.2% over the past year. This hints that the market may be warming back up to its story after a tougher 3 and 5 year...
ENXTPA:INF
ENXTPA:INFIT

European Dividend Stocks To Consider In December 2025

As the European market experiences mixed returns with a slight uptick in the STOXX Europe 600 Index amid hopes for interest rate cuts, investors are keenly observing inflation trends and economic growth revisions across the region. In this dynamic environment, dividend stocks can offer stability and income potential, making them a compelling consideration for those looking to navigate these uncertain times.
ENXTPA:CDI
ENXTPA:CDILuxury

Christian Dior (ENXTPA:CDI): Reassessing Valuation After a Recent Share Price Recovery

Christian Dior (ENXTPA:CDI) has quietly climbed about 24% over the past 3 months, even as this year’s performance looks more muted. That gap alone is making long term investors pause and reassess. See our latest analysis for Christian Dior. While the year to date share price return is still slightly negative, that 24% 3 month share price gain and a modest 1 year total shareholder return of 3.3% suggest momentum has started to rebuild as investors warm to Christian Dior’s longer term prospects...
ENXTPA:WLN
ENXTPA:WLNDiversified Financial

Worldline (ENXTPA:WLN) Valuation Reset After Kepler Cheuvreux Downgrade and Planned Capital Increase

Worldline (ENXTPA:WLN) is back under pressure after Kepler Cheuvreux cut its rating, highlighting a planned €500 million capital increase, weak free cash flow, and sizable refinancing needs later this decade. See our latest analysis for Worldline. The downgrade and capital increase plan arrive after a bruising stretch, with the 30 day share price return of minus 34.32 percent and year to date share price return of minus 83.67 percent underscoring a long running collapse in total shareholder...
ENXTPA:VIE
ENXTPA:VIEIntegrated Utilities

Is Veolia Environnement Still Attractively Priced After Its Strong Multi Year Share Price Run?

If you have ever wondered whether Veolia Environnement at around €29.74 is still good value after its strong run, you are not alone. This article is designed to cut through the noise for you. The stock is up about 1.3% over the last week, 3.9% over the past month, and 9.2% year to date, building on gains of 13.7% over 1 year, 37.4% over 3 years, and 87.7% over 5 years. This naturally raises the question of how much upside is left from here. Recent moves have come against a backdrop of...
ENXTPA:CDI
ENXTPA:CDILuxury

Does Dior’s Recovery Signal a Long Term Value Opportunity in 2025?

Wondering if Christian Dior at €593.5 is quietly trading at a bargain or already priced for perfection? This article breaks down what the numbers are really saying about the stock's value. Over the last week the share price is up 2.5% and it has gained 4.6% over the past month, but that still sits against a slightly negative YTD return of -1.2% and a more modest 7.5% gain over the past year. Recent market interest has been shaped by ongoing discussions around the resilience of global luxury...
ENXTPA:ASY
ENXTPA:ASYProfessional Services

Assystem And 2 More European Companies Estimated To Be Priced Below Their Intrinsic Value

As European markets continue to show resilience, with the STOXX Europe 600 Index rising by 2.35% and major single-country indexes also posting gains, investors are increasingly focused on finding opportunities that may be undervalued amidst a relatively stable inflation environment. In such conditions, stocks that are priced below their intrinsic value present an attractive proposition for those looking to capitalize on potential market inefficiencies and long-term growth prospects.